Deal Watch: Takeda Continues Shire Merger Prep With Out-License Of Relugolix Rights
As it narrows focus to core therapeutic areas ahead of acquiring Shire, Takeda sends uterine fibroid and endometriosis rights to compatriot firm ASKA. Zai Lab and Crescendo team up on antibody candidate for inflammatory indications.
You may also be interested in...
Brii Bio: Partnering To Bring Innovation To China
Emerging Company Profile: Brii Bio has been set up in Shanghai with robust initial funding and a handful of founding partnerships to help in its goal of accelerating innovation and optimizing access to the latest medicines for Chinese patients, with a focus on treatments for chronic illnesses with significant burdens, including infectious diseases, liver and lung disorders.
Venture Funding Deals: Two Companies With China Ties Raise $260m Each
Suzhou-based immuno-oncology specialist CStone raised a $260m Series B round and Brii launched with $260m in Series A cash to develop drugs for the China market. Also, multiple start-ups launched recently with more than $50m in Series A rounds, including Ansun, Beam, Casma, Celsius and Neurana.
Glenmark Sets Sights On Regional Out-Licensing, Lot Riding On US Rhinitis NDA
With a basket of interesting R&D assets in hand, India’s Glenmark says it is pursuing regional out-licensing deals, including in Japan and China, for some of its molecules. Expectations are also running high on the firm’s first US NDA submission for seasonal allergic rhinitis.